Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 8, 2012 - Issue 3
Submit an article Journal homepage
962
Views
24
CrossRef citations to date
0
Altmetric
Research Paper

Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine

Koen Van Herck Vaccine & Infectious Disease Institute (WHO Collaborating Centre); Centre for the Evaluation of Vaccination; Antwerpen, Belgium; Department of Public Health; Ghent University; Ghent, Belgium
,
Priya Diana Crasta GlaxoSmithKline Biologicals; Wavre, Belgium
,
Marc Messier GlaxoSmithKline Biologicals; Wavre, Belgium
,
Karin Hardt GlaxoSmithKline Biologicals; Wavre, Belgium
&
Pierre Van Damme Vaccine & Infectious Disease Institute (WHO Collaborating Centre); Centre for the Evaluation of Vaccination; Antwerpen, BelgiumCorrespondence[email protected]
Pages 323-327 | Published online: 13 Feb 2012

References

  • World Health Organization (WHO). 2000. Hepatitis A position paper. Wkly Epidemiol Rec 75:38–42. World Health Organisation, Dept. of Communicable diseases surveillance and Response. WHO/CDC/CSR/LYO/2002.2: Hepatitis B. Available: http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf. [Accessed on August 05, 2011].
  • Andersson KL, Friedman LS, Hepatitis A. A travelling target. Arch Intern Med 2010; 20:1818 - 9; http://dx.doi.org/10.1001/archinternmed.2010.412
  • Askling HH, Rombo L, Andersson Y, Martin S, Ekdahl K. Hepatitis A risk in travelers. J Travel Med 2009; 16:233 - 8; http://dx.doi.org/10.1111/j.1708-8305.2009.00307.x; PMID: 19674261
  • André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 2002; 1:9 - 23; http://dx.doi.org/10.1586/14760584.1.1.9; PMID: 12908508
  • Nothdurft HD. Hepatitis A vaccines. Expert Rev Vaccines 2008; 7:535 - 45; http://dx.doi.org/10.1586/14760584.7.5.535; PMID: 18564009
  • Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 2005; 4:459 - 71; http://dx.doi.org/10.1586/14760584.4.4.459; PMID: 16117704
  • Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 2008; 198:1776 - 82; http://dx.doi.org/10.1086/593335; PMID: 18976095
  • López EL, Contrini MM, Mistchenko A, Debbag R. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J 2010; 29:568 - 70; PMID: 20195189
  • Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004; 72:194 - 6; http://dx.doi.org/10.1002/jmv.10574; PMID: 14695659
  • Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol 2011; 83:1885 - 91; http://dx.doi.org/10.1002/jmv.22200; PMID: 21915861
  • Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63:1 - 7; http://dx.doi.org/10.1002/1096-9071(200101)63:1<1::AID-JMV1000>3.0.CO;2-U; PMID: 11130881
  • Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007; 25:927 - 31; http://dx.doi.org/10.1016/j.vaccine.2006.08.044; PMID: 17005304
  • Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, Briantais P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000; 60:1 - 7; http://dx.doi.org/10.1002/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H; PMID: 10568755
  • Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63:1 - 7; http://dx.doi.org/10.1002/1096-9071(200101)63:1<1::AID-JMV1000>3.0.CO;2-U; PMID: 11130881
  • Van Damme P, Matheï C, Thoelen S, Meheus A, Safary A, André FE. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994; 44:435 - 41; http://dx.doi.org/10.1002/jmv.1890440422; PMID: 7897376

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.